Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when RVMD files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRevolution Medicines R&D President Steve Kelsey to retire Jan 2027, transitions to advisor Jul 2026
Filed June 22, 2026 · Period ending June 18, 2026 · ~1 min read
Key Changes
-
high
Steve Kelsey, President of R&D, announced retirement effective Jan 4, 2027, with transition to senior advisor to CEO starting Jul 1, 2026, providing six-month handoff period.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
Company contemplates appointing Kelsey to board of directors upon retirement, subject to board approval, retaining his expertise in governance role.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
Annual meeting elected two Class III directors: Mark Goldsmith with 157.7M votes for (98.0% of votes cast, 74.2% of shares outstanding), Alexis Borisy with 127.2M votes for (79.1% of votes cast, 59.8% of shares outstanding).
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR → -
low
Stockholders ratified PwC as auditor with 181.3M votes for (99.8% of votes cast, 85.3% of shares outstanding) and approved executive compensation with 155.1M votes for (96.5% of votes cast, 73.0% of shares outstanding).
Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR →
Summary
Revolution Medicines disclosed the planned retirement of Steve Kelsey, its President of Research and Development, effective January 4, 2027. Dr. Kelsey will transition to a senior advisor role to the CEO starting July 1, 2026, providing a six-month handoff period for continuity in the company's R&D operations.
The company is also considering appointing him to the board of directors upon retirement, which would retain his scientific and strategic expertise in a governance capacity. The filing also reported results from the 2026 annual meeting. Both director nominees were elected, though Alexis Borisy received notably lower support (79.1% of votes cast) compared to Mark Goldsmith (98.0%).
The auditor ratification and say-on-pay votes passed with strong support at 99.8% and 96.5% respectively, reflecting routine stockholder approval. For retail investors, the key development is the planned leadership transition in R&D, which appears orderly with a structured handoff period and potential continued board involvement.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Upon his retirement from the Company, Dr. Kelsey will be eligible to receive certain benefits under the Company’s retirement policy for equity awards.
Dr. Kelsey will receive retirement benefits under the company's equity award retirement policy when he retires in January 2027. The specific terms are not disclosed in this filing.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Revolution Medicines held its 2026 annual meeting, electing two directors, ratifying PwC as auditor, and approving executive compensation.
Added in current filing · verify on EDGAR →
Nominee | Votes For | Votes Withheld | Broker Non-Votes | Alexis Borisy | 127,181,172 | 33,660,532 | 20,813,641
Mark A. Goldsmith, M.D., Ph.D.
157,681,628 | 3,160,076 | 20,813,641
Stockholders elected two Class III directors to serve until 2029. Mark A. Goldsmith received 157,681,628 votes for (98.0% of votes cast), while Alexis Borisy received 127,181,172 votes for (79.1% of votes cast). Of the 212,592,561 shares outstanding and entitled to vote, Goldsmith received support from 74.2% of shares outstanding, while Borisy received support from 59.8% of shares outstanding. The lower support for Borisy reflects elevated opposition but both directors were elected.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Votes For | Votes Against | Abstentions | Broker Non-Votes | 155,110,825 | 5,554,146 | 176,733 | 20,813,641
Stockholders approved executive compensation on an advisory basis. The proposal passed with 155,110,825 votes for (96.5% of votes cast), representing 73.0% of shares outstanding. The 3.5% opposition is well below typical thresholds for concern and reflects strong stockholder support for the compensation program.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 29, 2026 · How we verify